Artículos de revistas sobre el tema "Ozanimod"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Ozanimod".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Daykin, Nicola. "Ozanimod for relapsing remitting multiple sclerosis and how Brexit changed the journey". Journal of Prescribing Practice 4, n.º 2 (2 de febrero de 2022): 64–71. http://dx.doi.org/10.12968/jprp.2022.4.2.64.
Texto completoHarris, Sarah, Jonathan Q. Tran, Harry Southworth, Collin M. Spencer, Bruce A. C. Cree y Scott S. Zamvil. "Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS". Neurology - Neuroimmunology Neuroinflammation 7, n.º 5 (31 de julio de 2020): e839. http://dx.doi.org/10.1212/nxi.0000000000000839.
Texto completoCohen, Jeffrey A., Giancarlo Comi, Douglas L. Arnold, Amit Bar-Or, Krzysztof W. Selmaj, Lawrence Steinman, Eva K. Havrdová et al. "Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study". Multiple Sclerosis Journal 25, n.º 9 (25 de julio de 2018): 1255–62. http://dx.doi.org/10.1177/1352458518789884.
Texto completoPanaccione, R., S. Danese, D. C. Wolf, J. B. Canavan, A. Jain, H. Wu, A. Petersen, A. Afzali y M. T. Abreu. "P464 Effects of ozanimod on histologic remission and mucosal healing over 3 years of continuous treatment in patients with ulcerative colitis". Journal of Crohn's and Colitis 17, Supplement_1 (30 de enero de 2023): i591—i593. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0594.
Texto completoSandborn, William, Brian Feagan, Douglas Wolf, Geert D’Haens, Séverine Vermeire, Stephen Hanauer, Subrata Ghosh, Harry Southworth y Sarah Harris. "EFFECT OF OZANIMOD ON FECAL CALPROTECTIN AND FECAL LACTOFERRIN, BIOMARKERS OF INTESTINAL INFLAMMATION, IN THE PHASE 2 TOUCHSTONE STUDY OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS". Inflammatory Bowel Diseases 27, Supplement_1 (1 de enero de 2021): S6. http://dx.doi.org/10.1093/ibd/izaa347.014.
Texto completoArmuzzi, A., R. K. Cross, G. Lichtenstein, J. Calkwood, A. Pai, M. Pondel, H. A. Ahmad et al. "DOP45 Long-term cardiac safety of ozanimod in phase 3 clinical program of Ulcerative Colitis and relapsing multiple sclerosis". Journal of Crohn's and Colitis 16, Supplement_1 (1 de enero de 2022): i094—i095. http://dx.doi.org/10.1093/ecco-jcc/jjab232.084.
Texto completoSiegmund, B., J. Axelrad, M. Pondel, M. T. Osterman, H. A. Ahmad, A. Memaj, M. Regueiro, A. Armuzzi y A. Afzali. "DOP43 Rapidity of ozanimod-induced symptomatic response and remission in patients with moderately to severely active Ulcerative Colitis: Results from the induction period of True North". Journal of Crohn's and Colitis 16, Supplement_1 (1 de enero de 2022): i092—i093. http://dx.doi.org/10.1093/ecco-jcc/jjab232.082.
Texto completoDubinsky, M. C., U. Mahadevan, L. Charles, S. Afsari, A. Henry, G. Comi, K. Selmaj y C. J. van der Woude. "DOP53 Pregnancy outcomes in the ozanimod clinical development program in relapsing multiple sclerosis, Ulcerative Colitis, and Crohn’s Disease". Journal of Crohn's and Colitis 15, Supplement_1 (1 de mayo de 2021): S088—S089. http://dx.doi.org/10.1093/ecco-jcc/jjab073.092.
Texto completoShen, J., D. Tatosian, L. Sid-Otmane, N. Teuscher, L. Chen, P. Zhang, G. S. Tirucherai, D. Chitakara y C. Marta. "P332 Population pharmacokinetics of ozanimod and active metabolite CC112273 in patients with ulcerative colitis". Journal of Crohn's and Colitis 15, Supplement_1 (1 de mayo de 2021): S355—S357. http://dx.doi.org/10.1093/ecco-jcc/jjab076.456.
Texto completoShen, Jun, Daniel Tatosian, Lamia Sid-Otmane, Nathan Teuscher, Lu Chen, Peijin Zhang, Giridhar Tirucherai, Denesh Chitkara y Cecilia Marta. "POPULATION PHARMACOKINETICS OF OZANIMOD AND ACTIVE METABOLITE CC112273 IN PATIENTS WITH ULCERATIVE COLITIS". Inflammatory Bowel Diseases 28, Supplement_1 (22 de enero de 2022): S17—S18. http://dx.doi.org/10.1093/ibd/izac015.025.
Texto completoSwallow, Elyse, Oscar Patterson-Lomba, Lei Yin, Rina Mehta, Corey Pelletier, David Kao, James K. Sheffield, Tim Stonehouse y James Signorovitch. "Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis". Journal of Comparative Effectiveness Research 9, n.º 4 (marzo de 2020): 275–85. http://dx.doi.org/10.2217/cer-2019-0169.
Texto completoBonek, Robert. "Ozanimod w terapii rzutowo-remisyjnej postaci stwardnienia rozsianego – opisy przypadków". Medycyna Faktów 15, n.º 2 (55) (20 de junio de 2022): 236–39. http://dx.doi.org/10.24292/01.mf.0222.18.
Texto completoPanaccione, R., S. Danese, D. C. Wolf, J. B. Canavan, A. Jain, H. Wu, A. Petersen, L. Charles, A. Afzali y M. T. Abreu. "P405 Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension". Journal of Crohn's and Colitis 17, Supplement_1 (30 de enero de 2023): i534—i535. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0535.
Texto completoSands, B. E., A. Dignass, P. Irving, M. Chiorean, M. Long, D. Eren, H. A. Ahmad et al. "P316 Ozanimod is an efficacious oral therapy after, 5-ASA failure in immunomodulator- and biologic-naive patients with ulcerative colitis: post hoc analysis from True North". Journal of Crohn's and Colitis 16, Supplement_1 (1 de enero de 2022): i339—i340. http://dx.doi.org/10.1093/ecco-jcc/jjab232.443.
Texto completoDignass, A., M. Regueiro, J. F. Colombel, A. Jain, J. B. Canavan, H. Wu, G. Lawlor, M. T. Osterman, S. Vermeire y D. T. Rubin. "P687 Durability of recaptured response to ozanimod during the True North open-label extension". Journal of Crohn's and Colitis 17, Supplement_1 (30 de enero de 2023): i817—i818. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0817.
Texto completoDanese, S., M. T. Abreu, D. C. Wolf, J. B. Canavan, A. Jain, H. Wu, A. Petersen, L. Charles, R. Panaccione y A. Afzali. "DOP37 Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study". Journal of Crohn's and Colitis 17, Supplement_1 (30 de enero de 2023): i101—i102. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0077.
Texto completoVermeire, S., J. F. Colombel, M. V. Chiorean, S. Ghosh, A. Jain, G. Lawlor, M. T. Osterman, H. Wu, J. B. Canavan y D. T. Rubin. "P773 Extended induction in the True North open-label extension study: clinical outcomes of ~2 years of ozanimod treatment". Journal of Crohn's and Colitis 17, Supplement_1 (30 de enero de 2023): i903—i904. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0903.
Texto completoLamb, Yvette N. "Ozanimod: First Approval". Drugs 80, n.º 8 (8 de mayo de 2020): 841–48. http://dx.doi.org/10.1007/s40265-020-01319-7.
Texto completoFloden, L., T. P. Pham, J. Kumar, B. Becker, J. W. Shaw y T. Tencer. "P468 Evaluation of work productivity and activity impairment in moderate-to-severe ulcerative colitis participants treated with ozanimod in the phase 3 True North study". Journal of Crohn's and Colitis 16, Supplement_1 (1 de enero de 2022): i441—i442. http://dx.doi.org/10.1093/ecco-jcc/jjab232.595.
Texto completoReinisch, W., J. Axelrad, H. A. Ahmad, M. Pondel, S. Ather, A. Elegbe, C. Sninsky y R. Longman. "P431 Early mucosal healing at week, 10 with ozanimod predicts clinical outcomes at week, 52: Post hoc analysis of the phase, 3 True North clinical trial". Journal of Crohn's and Colitis 16, Supplement_1 (1 de enero de 2022): i415. http://dx.doi.org/10.1093/ecco-jcc/jjab232.558.
Texto completoDanese, S., M. T. Abreu, A. Afzali, J. B. Canavan, A. Jain, H. Wu, A. Petersen, R. Panaccione y D. C. Wolf. "P719 Symptomatic improvement and long-term stability of ulcerative colitis symptoms over 3 years of ozanimod treatment". Journal of Crohn's and Colitis 17, Supplement_1 (30 de enero de 2023): i848—i850. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0849.
Texto completoVermeire, S., J. F. Colombel, D. T. Rubin, S. Ghosh, A. Jain, G. Lawlor, M. T. Osterman, H. Wu, J. B. Canavan y M. V. Chiorean. "P715 Achievement and maintenance of endoscopic, histologic, and combined outcomes after extended induction in Week 10 nonresponders of ozanimod: 2-year interim analysis of the True North open-label extension study". Journal of Crohn's and Colitis 17, Supplement_1 (30 de enero de 2023): i844—i845. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0845.
Texto completoCohen, Nathaniel, Tenzin Choden, David Choi, Noa Cleveland, Russell Cohen, Sushila Dalal, Atsushi Sakuraba, Ira Hanan y David Rubin. "REAL WORLD EFFECTIVENESS AND SAFETY OF OZANIMOD: INITIAL RESULTS FROM A LARGE TERTIARY CENTER". Inflammatory Bowel Diseases 28, Supplement_1 (22 de enero de 2022): S109. http://dx.doi.org/10.1093/ibd/izac015.175.
Texto completoWendt, Trevor S., Yu Jing Li y Rayna J. Gonzales. "Ozanimod, an S1PR1 ligand, attenuates hypoxia plus glucose deprivation-induced autophagic flux and phenotypic switching in human brain VSM cells". American Journal of Physiology-Cell Physiology 320, n.º 6 (1 de junio de 2021): C1055—C1073. http://dx.doi.org/10.1152/ajpcell.00044.2021.
Texto completoUngaro, R., C. A. Siegel, B. A. C. Cree, K. W. Selmaj, H. A. Ahmad, A. Pai, S. Ather et al. "P486 Treatment-emergent COVID-19 infections in ozanimod ulcerative colitis and multiple sclerosis clinical trials". Journal of Crohn's and Colitis 16, Supplement_1 (1 de enero de 2022): i452. http://dx.doi.org/10.1093/ecco-jcc/jjab232.613.
Texto completoVermeire, S., A. Dignass, J. F. Colombel, A. Jain, J. B. Canavan, H. Wu, G. Lawlor, M. T. Osterman, D. T. Rubin y M. Regueiro. "DOP39 Endoscopic, histologic, and combined outcomes with reinitiation of ozanimod after temporary discontinuation: 2-year interim analysis of the True North open-label extension study". Journal of Crohn's and Colitis 17, Supplement_1 (30 de enero de 2023): i103—i104. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0079.
Texto completoKuczynski, Andrea M. y Jiwon Oh. "Ozanimod for the treatment of relapsing forms of multiple sclerosis". Neurodegenerative Disease Management 11, n.º 3 (junio de 2021): 207–20. http://dx.doi.org/10.2217/nmt-2021-0005.
Texto completoBrockmeier, Bernd. ""Geringer Zusatznutzen" für Ozanimod". NeuroTransmitter 32, n.º 5 (mayo de 2021): 16–17. http://dx.doi.org/10.1007/s15016-021-9149-y.
Texto completoKathmann, Wiebke. "Ozanimod als neue Behandlungsoption". Gastro-News 9, n.º 2 (abril de 2022): 60. http://dx.doi.org/10.1007/s15036-022-2493-3.
Texto completoHof, Teresa y Peter Hasselblatt. "Ozanimod bei Colitis ulcerosa". Gastro-News 8, n.º 6 (diciembre de 2021): 28–29. http://dx.doi.org/10.1007/s15036-021-2431-9.
Texto completoCiftci-Kavaklioglu, Beyza y E. Ann Yeh. "Ozanimod in Multiple Sclerosis". European Neurological Review 14, n.º 2 (2019): 73. http://dx.doi.org/10.17925/enr.2019.14.2.73.
Texto completoMohamed, Rana, Cody Kern, Aaron Fein, Terrence Barrett y Courtney Perry. "SUCCESSFUL CLEARANCE OF CYTOMEGALOVIRUS COLITIS IN ACUTE SEVERE ULCERATIVE COLITIS DURING INDUCTION OF OZANIMOD". Inflammatory Bowel Diseases 28, Supplement_1 (22 de enero de 2022): S110—S111. http://dx.doi.org/10.1093/ibd/izac015.177.
Texto completoLassiter, Grace, Carlie Melancon, Tyler Rooney, Anne-Marie Murat, Jessica S. Kaye, Adam M. Kaye, Rachel J. Kaye et al. "Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects". Neurology International 12, n.º 3 (3 de diciembre de 2020): 89–108. http://dx.doi.org/10.3390/neurolint12030016.
Texto completoCaldera, F., R. Maddux, R. Ungaro, A. Kaur, E. Brown, S. Hu, J. K. Sheffield, D. Silva, S. Harris y B. A. C. Cree. "P516 Humoral immune responses to SARS-CoV-2 vaccines in an ozanimod open-label extension study". Journal of Crohn's and Colitis 17, Supplement_1 (30 de enero de 2023): i643—i644. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0646.
Texto completoDignass, A., M. Regueiro, J. F. Colombel, A. Jain, J. B. Canavan, H. Wu, G. Lawlor, M. T. Osterman, S. Vermeire y D. T. Rubin. "DOP43 Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patients". Journal of Crohn's and Colitis 17, Supplement_1 (30 de enero de 2023): i110—i111. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0083.
Texto completoTatosian, D., J. Shen, L. Chen, J. Lavigne, N. Teuscher, S. Harris, D. Chitkara, G. S. Tirucherai y C. Marta. "P315 Population pharmacokinetics and pharmacodynamics of ozanimod in ulcerative colitis". Journal of Crohn's and Colitis 15, Supplement_1 (1 de mayo de 2021): S341—S342. http://dx.doi.org/10.1093/ecco-jcc/jjab076.439.
Texto completoTatosian, Daniel, Jun Shen, Lu Chen, Jean Lavigne, Nathan Teuscher, Sarah Harris, Denesh Chitkara, Giridhar Tirucherai y Cecilia Marta. "POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF OZANIMOD IN ULCERATIVE COLITIS". Inflammatory Bowel Diseases 28, Supplement_1 (22 de enero de 2022): S16. http://dx.doi.org/10.1093/ibd/izac015.024.
Texto completoGroh, Jan. "Ozanimod senkt Schubrate bei RRMS". InFo Neurologie + Psychiatrie 22, n.º 11 (noviembre de 2020): 50. http://dx.doi.org/10.1007/s15005-020-1519-7.
Texto completoAlaskar, Dimah, Zainab AlMusa y Turki AlAmeel. "Letter: Ozanimod and latent tuberculosis". Alimentary Pharmacology & Therapeutics 57, n.º 3 (15 de enero de 2023): 353–54. http://dx.doi.org/10.1111/apt.17311.
Texto completoDanese, S., J. F. Colombel, T. Ponich, I. Jovanovic, P. Bossuyt, R. Longman, O. Alekseeva et al. "DOP44 Long-term use of ozanimod in patients with moderately to severely active Ulcerative Colitis". Journal of Crohn's and Colitis 16, Supplement_1 (1 de enero de 2022): i093—i094. http://dx.doi.org/10.1093/ecco-jcc/jjab232.083.
Texto completoSiegmund, B., G. Y. Melmed, P. M. Irving, A. Pai, A. Patel, J. K. Sheffield, F. Caldera, B. A. C. Cree y M. C. Dubinsky. "P402 Incidence and outcomes of herpes zoster in the ozanimod phase, 3 ulcerative colitis and relapsing multiple sclerosis clinical program". Journal of Crohn's and Colitis 16, Supplement_1 (1 de enero de 2022): i395—i396. http://dx.doi.org/10.1093/ecco-jcc/jjab232.529.
Texto completoCohen, N. A., D. Choi, N. Garcia, N. Choi, E. Picker, N. Krugliak-Cleveland, R. Cohen et al. "P562 Real world effectiveness and safety of ozanimod: One-year follow-up from a large tertiary center". Journal of Crohn's and Colitis 17, Supplement_1 (30 de enero de 2023): i692—i693. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0692.
Texto completoSandborn, William J., Brian G. Feagan, Stephen Hanauer, Severine Vermeire, Subrata Ghosh, Wenzhong J. Liu, AnnKatrin Petersen et al. "Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study". Journal of Crohn's and Colitis 15, n.º 7 (13 de enero de 2021): 1120–29. http://dx.doi.org/10.1093/ecco-jcc/jjab012.
Texto completoAntonelli, E., R. Del Sordo, O. Morelli, V. Villanacci y G. Bassotti. "Update on ozanimod for ulcerative colitis". Drugs of Today 58, n.º 7 (2022): 351. http://dx.doi.org/10.1358/dot.2022.58.7.3408818.
Texto completoEiden, Petra. "Frühe Reduktion der Läsionslast unter Ozanimod". InFo Neurologie + Psychiatrie 23, n.º 7-8 (agosto de 2021): 53. http://dx.doi.org/10.1007/s15005-021-2037-y.
Texto completoRay, Katrina. "Ozanimod is efficacious in ulcerative colitis". Nature Reviews Gastroenterology & Hepatology 18, n.º 11 (1 de octubre de 2021): 748. http://dx.doi.org/10.1038/s41575-021-00532-3.
Texto completoAnja, Borchers. "MS-Therapie: Aktuelle Daten zu Ozanimod". Nervenheilkunde 37, n.º 03 (febrero de 2018): 216. http://dx.doi.org/10.1055/s-0038-1638278.
Texto completoOttenjann, Henrike. ""Hit smart and early" mit Ozanimod". InFo Neurologie + Psychiatrie 25, n.º 2 (febrero de 2023): 53. http://dx.doi.org/10.1007/s15005-023-3181-3.
Texto completoSamjoo, Imtiaz A., Evelyn Worthington, Christopher Drudge, Melody Zhao, Chris Cameron, Dieter A. Häring, Dee Stoneman, Luisa Klotz y Nicholas Adlard. "Efficacy classification of modern therapies in multiple sclerosis". Journal of Comparative Effectiveness Research 10, n.º 6 (abril de 2021): 495–507. http://dx.doi.org/10.2217/cer-2020-0267.
Texto completoPotì, Francesco, Carmine Giorgio, Irene Zini, Jerzy-Roch Nofer, Valentina Vivo, Simone Palese, Vigilio Ballabeni, Elisabetta Barocelli y Simona Bertoni. "Impact of S1P Mimetics on Mesenteric Ischemia/Reperfusion Injury". Pharmaceuticals 13, n.º 10 (9 de octubre de 2020): 298. http://dx.doi.org/10.3390/ph13100298.
Texto completo